{"database": "lobbying", "table": "lobbying_activities", "rows": [[2186896, "5d5c62e4-4cd0-49f6-93dd-9a99b66f7e84", "Q3", "DAVIS & HARMAN LLP", 11674, "EMERGENT BIOSOLUTIONS, INC.", 2018, "third_quarter", "DIS", "FY 2019 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. government. Re-authorization of the Pandemic and All-Hazards Preparedness Act.  NDAA - provisions related to biological and chemical defense.", null, 20000, null, 0, 0, "2018-10-17T09:32:16.287000-04:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["2186896"], "units": {}, "query_ms": 20.103573973756284, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}